Edesa Biotech Net Income
| EDSA Stock | USD 1.15 0.03 2.68% |
As of the 9th of February, Edesa Biotech shows the Variance of 14.05, standard deviation of 3.75, and Mean Deviation of 2.6. Edesa Biotech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Edesa Biotech Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 128.5 K | Revenue | Earnings Share (1.27) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -6.5 M | -6.8 M | |
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -6.5 M | -6.8 M | |
| Net Loss | (46.75) | (49.08) | |
| Net Income Per E B T | 1.00 | 1.10 |
Edesa | Net Income | Build AI portfolio with Edesa Stock |
Analyzing Edesa Biotech's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Edesa Biotech's current valuation and future prospects.
Latest Edesa Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Edesa Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Edesa Biotech financial statement analysis. It represents the amount of money remaining after all of Edesa Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Edesa Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edesa Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.19 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Edesa Net Income Regression Statistics
| Arithmetic Mean | (7,147,074) | |
| Coefficient Of Variation | (62.30) | |
| Mean Deviation | 3,164,189 | |
| Median | (6,364,230) | |
| Standard Deviation | 4,452,470 | |
| Sample Variance | 19.8T | |
| Range | 17.5M | |
| R-Value | (0.23) | |
| Mean Square Error | 20T | |
| R-Squared | 0.05 | |
| Significance | 0.37 | |
| Slope | (202,731) | |
| Total Sum of Squares | 317.2T |
Edesa Net Income History
Other Fundumenentals of Edesa Biotech
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Edesa Biotech Net Income component correlations
Edesa Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Edesa Biotech is extremely important. It helps to project a fair market value of Edesa Stock properly, considering its historical fundamentals such as Net Income. Since Edesa Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edesa Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edesa Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Edesa Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Edesa Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Edesa Biotech.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Edesa Biotech on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Edesa Biotech or generate 0.0% return on investment in Edesa Biotech over 90 days. Edesa Biotech is related to or competes with BioRestorative Therapies, Dogwood Therapeutics, Cocrystal Pharma, OSR Holdings, Traws Pharma, Immuron, and Eterna Therapeutics. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage d... More
Edesa Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Edesa Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Edesa Biotech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 21.29 | |||
| Value At Risk | (6.47) | |||
| Potential Upside | 5.13 |
Edesa Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edesa Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Edesa Biotech's standard deviation. In reality, there are many statistical measures that can use Edesa Biotech historical prices to predict the future Edesa Biotech's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (1.89) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Edesa Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Edesa Biotech February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (1.88) | |||
| Mean Deviation | 2.6 | |||
| Coefficient Of Variation | (630.95) | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.05 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (1.89) | |||
| Maximum Drawdown | 21.29 | |||
| Value At Risk | (6.47) | |||
| Potential Upside | 5.13 | |||
| Skewness | (0.78) | |||
| Kurtosis | 4.43 |
Edesa Biotech Backtested Returns
Edesa Biotech secures Sharpe Ratio (or Efficiency) of -0.17, which denotes the company had a -0.17 % return per unit of risk over the last 3 months. Edesa Biotech exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Edesa Biotech's Variance of 14.05, standard deviation of 3.75, and Mean Deviation of 2.6 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.32, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edesa Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Edesa Biotech is expected to be smaller as well. At this point, Edesa Biotech has a negative expected return of -0.66%. Please make sure to confirm Edesa Biotech's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Edesa Biotech performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.85 |
Very good predictability
Edesa Biotech has very good predictability. Overlapping area represents the amount of predictability between Edesa Biotech time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Edesa Biotech price movement. The serial correlation of 0.85 indicates that around 85.0% of current Edesa Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.85 | |
| Spearman Rank Test | 0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Edesa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Edesa Biotech reported net income of (7.19 Million). This is 102.11% lower than that of the Biotechnology sector and 110.26% lower than that of the Health Care industry. The net income for all United States stocks is 101.26% higher than that of the company.
Edesa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in net income category among its peers.
Edesa Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Edesa Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Edesa Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Edesa Biotech's value.| Shares | Efficient Wealth Management Llc | 2025-03-31 | 242 | Td Waterhouse Canada Inc | 2025-06-30 | 142 | Fifth Third Bancorp | 2025-06-30 | 100.0 | Bank Of America Corp | 2025-06-30 | 54.0 | Global Retirement Partners, Llc. | 2025-06-30 | 25.0 | Lri Investments, Llc | 2025-06-30 | 1.0 | Crédit Agricole S.a. | 2025-03-31 | 1.0 | Allsquare Wealth Management Llc | 2025-06-30 | 1.0 | Dogwood Wealth Management Llc | 2025-06-30 | 1.0 | Velan Capital Investment Management Lp | 2025-06-30 | 687.5 K | Rubric Capital Management Lp | 2025-06-30 | 687.5 K |
Edesa Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 8.32 M | ||||
| Shares Outstanding | 8.33 M | ||||
| Shares Owned By Insiders | 17.06 % | ||||
| Shares Owned By Institutions | 34.41 % | ||||
| Number Of Shares Shorted | 13.96 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 2.92 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (7.07 M) | ||||
| Net Income | (7.19 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 1.21 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (7.32 M) | ||||
| Short Ratio | 0.30 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 0.21 | ||||
| Market Capitalization | 9.33 M | ||||
| Total Asset | 13.53 M | ||||
| Retained Earnings | (65.91 M) | ||||
| Working Capital | 10.43 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
| Net Asset | 13.53 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.